BIOCOS IKE

Their core work

BIOCOS is a Greek biotech SME that applies molecular biology and digital intelligence to two distinct problem domains: food authenticity and crisis response. Their early work focused on DNA-based authentication of Extra Virgin Olive Oil — using genetic markers to detect fraud and trace product origin. They have since expanded into AI-driven pandemic management, contributing to large-scale systems that combine machine learning, NLP, and bioinformatics to predict outbreaks and support decision-making during health crises. The connecting thread across both areas is their ability to turn biological data — whether DNA profiles or PCR diagnostics — into actionable intelligence.

What they specialise in

How they've shifted over time

BIOCOS entered H2020 in 2019 with a focused biotechnology proposition: DNA authentication for high-value food products, specifically Greek olive oil. Their first project (AUTHEVOO) was a small SME Phase 1 feasibility study — typical of an SME testing a market-ready idea with no recorded keyword taxonomy. Within a year, their profile expanded dramatically: STAMINA brought them into pandemic crisis management, adding AI, NLP, machine learning, and public health preparedness to their portfolio. The shift suggests they leveraged their core bioinformatics and diagnostics capabilities — PCR, molecular analysis — to enter a new domain where biological data feeds digital decision support systems.

BIOCOS is moving toward the intersection of bioinformatics and AI-powered public health security, where their molecular diagnostics background becomes an input layer for predictive, large-scale crisis response systems.

How they like to work

BIOCOS operates both as an independent innovator and as a specialist contributor within large multi-partner consortia. They led AUTHEVOO as coordinator — a small, focused SME Phase 1 project — while joining STAMINA as a participant in a much larger Innovation Action. With 39 unique partners across 17 countries from just two projects, the breadth of their network is disproportionately large for their size, suggesting they are valued as a specialized technical contributor that larger consortia seek out for their particular molecular biology and bioinformatics skills.

Despite only two projects, BIOCOS has accumulated 39 consortium partners across 17 countries — most of this reach is attributable to STAMINA, which appears to have been a large, geographically diverse Innovation Action. Their network is European in scope, with likely representation from countries involved in pandemic preparedness and crisis management research.

What sets them apart

BIOCOS occupies an unusual niche as a small Greek company that bridges wet-lab molecular biology — DNA analysis, PCR, bioinformatics — with AI and machine learning applications in health security. Most AI crisis management firms lack the biological diagnostics depth; most biotech firms lack the AI/ML capability for event prediction and decision support. That combination made them relevant inside a large pandemic preparedness consortium despite being an SME, and it gives them a credible story across two very different buyer communities.

Highlights from their portfolio

• STAMINA
  The largest funded project (EUR 200,330) and most complex — an Innovation Action combining AI, NLP, bioinformatics, and Common Operational Picture frameworks for pandemic crisis prediction, placing a small Greek SME inside a major cross-European security and health consortium.
• AUTHEVOO
  As coordinator, BIOCOS led a commercially grounded feasibility study on DNA-based olive oil authentication — a product-ready proposition targeting one of Greece's most economically significant export categories and a persistent food fraud problem in EU markets.